Mirati Therapeutics

Closely Watched Mirati Reveals Results to Rival Amgen Drug
Closely Watched Mirati Reveals Results to Rival Amgen Drug
Bloomberg
Mirati Therapeutics
Amgen
adagrasib
lung cancer
Flag link:
Mirati's Sitravatinib Shows Promising Phase II Results in Urothelial Cancer Patients
Mirati's Sitravatinib Shows Promising Phase II Results in Urothelial Cancer Patients
BioSpace
Mirati Therapeutics
sitravantinib
ESMO
urothelial cancer
Flag link:
Mirati's sitravatinib in combination with nivolumab shows 37% response rate in urothelial cancer
Mirati's sitravatinib in combination with nivolumab shows 37% response rate in urothelial cancer
Seeking Alpha
ESMO
Mirati Therapeutics
clinical trials
sitravantinib
Opdivo
urothelial cancer
Flag link:
Top 7 Companies in Biotech Beach by Revenue
Top 7 Companies in Biotech Beach by Revenue
BioSpace
Biotech Beach
San Diego
California
Amgen
Neurocrine
Acadia Pharmaceuticals
Retrophin
Tocagen
Mirati Therapeutics
AnaptysBio
Flag link:
Triple meeting – Mirati avoids the worst-case scenario
Triple meeting – Mirati avoids the worst-case scenario
EP Vantage
Mirati Therapeutics
MRTX849
lung cancer
colorectal cancer
Flag link:
The Week Ahead In Biotech: Adcom Test For Agile; Pfizer, Merck Lead Earnings
The Week Ahead In Biotech: Adcom Test For Agile; Pfizer, Merck Lead Earnings
Yahoo/Benzinga
Adamis Pharmaceuticals
Redhill Biopharma
Amag Pharmaceuticals
Arqule
Agile Therapeutics
Agios Pharmaceuticals
Deciphera
Mirati Therapeutics
Sutro BioPharma
Merck
Pfizer
Amgen
EXACT Sciences
Bristol-Myers Squibb
Celgene
Oyster Point Pharma
Flag link:
Mirati sets date for closely watched clinical KRAS readout
Mirati sets date for closely watched clinical KRAS readout
Fierce Biotech
Mirati Therapeutics
KRAS
MRTX849
Amgen
cancer
Flag link:
3 Companies To Watch For At November’s Society for Immunotherapy of Cancer Meeting
3 Companies To Watch For At November’s Society for Immunotherapy of Cancer Meeting
Motley Fool
SITC
cancer immunotherapy
Autolus Therapeutics
Mirati Therapeutics
Nektar Therapeutics
Flag link:
4 Biotech Stocks With Big Catalysts in September
4 Biotech Stocks With Big Catalysts in September
Motley Fool
Amgen
AMG 510
Mirati Therapeutics
MRTX849
Eli Lilly
LOXO-292
Blueprint Me
Pralsetinibdicines
Flag link:
Mirati and Novartis Pair Up to Evaluate Drug Combinations to Target KRAS G12C Mutations
Mirati and Novartis Pair Up to Evaluate Drug Combinations to Target KRAS G12C Mutations
BioSpace
Mirati Therapeutics
Novartis
KRAS
solid tumors
Flag link:
3 Cancer Stocks Given a Lift by Amgen
3 Cancer Stocks Given a Lift by Amgen
Motley Fool
Amgen
KRAS
AMG 510
Mirati Therapeutics
Array Biopharma
Gilead Sciences
ASCO 2019
Flag link:
Here's Why Mirati Therapeutics Is Surging Today
Here's Why Mirati Therapeutics Is Surging Today
Motley Fool
Mirati Therapeutics
Amgen
KRAS inhibitors
MRTX849
AMG 510
Flag link:
Mirati Therapeutics Announces Positive Results in Immuno-Oncology Combination Trials
Mirati Therapeutics Announces Positive Results in Immuno-Oncology Combination Trials
CP Wire
Mirati Therapeutics
Opdivo
checkpoint inhibitors
non-small cell lung cancer
Flag link:
Mirati Therapeutics Announces Positive Results in Immuno-Oncology Combination Trials
Mirati Therapeutics
Opdivo
checkpoint inhibitors
non-small cell lung cancer
Flag link:
7 Biopharma Companies That Destroyed Shareholders Last Week
7 Biopharma Companies That Destroyed Shareholders Last Week
24/7 Wall St
ProNai
Adamis Pharmaceuticals
Ocular Therapeutics
Mirati Therapeutics
Immunomedics
Valeant Pharmacueticals
Biogen
Flag link:
This Past Week’s Top 5 Biotech Movers
This Past Week’s Top 5 Biotech Movers
24/7 Wall St
biotech
Akebia Therapeutics
Clovis Oncology
Mirati Therapeutics
Vivus
Vitae
Flag link:
AstraZeneca Oncology Partnerships To Help Recover Sales
AstraZeneca Oncology Partnerships To Help Recover Sales
Bidness ETC
AstraZeneca
oncology
Pfizer
Peregrine Pharmaceuticals
Heptares Therapeutics
Mirati Therapeutics
Juno Therapeutics
Flag link:
AstraZeneca plc (ADR) Strikes 2 Immuno-Oncology Deals; Are Its Efforts In The Right Direction?
AstraZeneca plc (ADR) Strikes 2 Immuno-Oncology Deals; Are Its Efforts In The Right Direction?
Bidness, ETC
immuno-oncology
AstraZeneca
HTL-1071
Heptares Therapeutics
Mirati Therapeutics
MedImmune
Flag link:
AstraZeneca ties up with little Mirati on another PD-L1 combo trial
AstraZeneca ties up with little Mirati on another PD-L1 combo trial
Fierce Biotech
AstraZeneca
PD-1 inhibitors
durvalumab
MedImmune
Mirati Therapeutics
Flag link:
Ignyta: Now Public With A Targeted Oncology Pipeline Poised For Success
Ignyta: Now Public With A Targeted Oncology Pipeline Poised For Success
Seeking Alpha
Ignyta
oncology
Clovis Oncology
Ariad Pharmaceuticals
Mirati Therapeutics
Tesaro
Puma Biotechnology
Flag link: